Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | BCL2 | P10415 | 5/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492258 | 0.91 | ALDH1A1 (0.35) | PIK3C2BPPARGDCTPP1MEN1KMT2A | |
| SCHEMBL6487607 | 0.91 | REN (0.38) | PIK3C2BPPARGBCL2MCL1DCTPP1 | |
| SCHEMBL6503787 | 0.90 | PIK3C2B (0.38) | PIK3C2BPPARGBCL2MCL1DCTPP1 | |
| SCHEMBL6491005 | 0.90 | BCL2 (0.47) | PIK3C2BBCL2MCL1MRGPRX4 | |
| SCHEMBL6491725 | 0.89 | PIK3C2B (0.37) | PIK3C2BBCL2MCL1DCTPP1MRGPRX4 | |
| SCHEMBL6492387 | 0.88 | PPARG (0.46) | PPARG | |
| SCHEMBL6488710 | 0.85 | BCL2 (0.39) | BCL2MCL1DCTPP1 | |
| SCHEMBL6495279 | 0.83 | MAPT (0.36) | PIK3C2BDCTPP1 | |
| SCHEMBL6500609 | 0.83 | DCTPP1 (0.38) | PIK3C2BBCL2MCL1DCTPP1KMT2A | |
| SCHEMBL6500643 | 0.82 | ALOX5AP (0.40) | PIK3C2BBCL2MCL1PTGER1DCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PIK3C2B 2433/4885PPARG 233/4885BCL2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.